THIRD PARTY MANUFACTURING PHARMA
We Emdikat Healthcare are engaged in contract manufacturing Services of wider range of tablets , capsules, injectables, dry syrups, Nutraceuticals.
Emdikat Healthcare its state-of-the-art ultra modem facility is set up in the northern indian state of himachal pradesh is who -GMP and ISO accredited offers commercial contract drug manufacturing for domestic & international market. As leading contract manufacturer in northern India with state of the art manufacturing facilities in tax free zone, with commitment towards working collaboratively with our customers. We are having capacity for large scale productions of tablets, capsules, dry syrups, syrups, neutraceuticals and injections. It is committed to provide quality branded medicines & generics at affordable prices to patients worldwide aiming to reduce health care costs. We uphold quality measures at all stages from material procurement, process optimization, formulation, testing and stability. Large scale production capacity and qualified & experienced production and quality control staff are a perfect combination at Emdikat Healthcare limited for sufficing the outsourcing or contract manufacturing requirements.
A ‘Contract Development and Manufacturing Organization’ (‘CDMO’), ‘sometimes called a’ ‘Contract Manufacturing Organization’ (‘CMO’), is an organization that serves the pharmaceutical industry and provides clients with comprehensive services from drug development through manufacture.Services offered by Emdikat include, but are not limited to: pre-formulation, formulation development, stability studies, method development, pre-clinical and Phase I clinical trial materials, late-stage clinical trial materials, formal stability, scale-up, registration batches and commercial production.
BENEFITS OF THIRD PARTY / CONTRACT MANUFACTURING
Outsourcing to a CDMO allows the pharmaceutical client to expand its technical resources without increased overhead. The client can then manage its internal resources and costs by focusing on core competencies and high-value projects while reducing or not adding infrastructure or technical staff. Virtual and specialty pharmaceutical companies are particularly well-suited to CDMO partnerships, and big pharmaceutical companies are beginning to view relationships with CDMOs as strategic rather than tactical.
Working with a CDMO also limits a client’s upfront capital investment for drug development, thus minimizing a project’s cost. By concentrating resources with a single-source provider, the outsourcing client can minimize technical transfer of projects or products, thereby reducing unforeseen costs and potentially speeding new products to market.